Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Elly Lugtenburg, JM Zijlstra, Jeanette Doorduijn, LH Bohmer, M Hoogendoorn, HW Berenschot, A Beeker, NC van der Burg-de Graauw, HC Schouten, YM Bilgin, MJ Kersten, HR Koene, AHE Herbers, D Jong, N Hijmering, King Lam, D Chitu, RE Brouwer, GW van Imhoff

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
Original languageUndefined/Unknown
JournalBritish Journal of Haematology
Publication statusPublished - 2019

Cite this